Lifeway Foods, Inc. (LWAY) Cash Flow Statement

The conversion profile has deteriorated sharply rather than gradually: the OCF/NI ratio fell from 1.96 in 2025Q3 to 0.11 in 2025Q4 and then to -2.67, implying that recent reported earnings are not translating into cash at the rate prior quarters suggested. Working capital absorbed $468K in 2026Q2 and $2.0M in 2026Q1, so the shortfall appears tied to both cash costs and cycle drag rather than a single non-recurring item. Read alongside the gross margin contraction to 19.5% noted in the income statement work, the weak conversion suggests profitability is now as fragile in cash terms as it is on the income statement.

The ten-quarter record shows an abrupt regime change: 2024 produced modestly positive FCF ($5.1M-$5.9M in the middle quarters), while the last three quarters have consumed roughly $32.9M cumulative, an order-of-magnitude shift that investors should treat as a new baseline until proven otherwise. Against packaged-food peers posting positive FCF margins (JJSF at 7.1%, SMPL at 8.6%, FRPT at 14.3%), LWAY's -13.2% latest reading implies the company is currently funding growth from the balance sheet rather than operations. The trajectory therefore contradicts any read-through that accelerating revenue growth is self-funding.

Capex running at roughly eight to ten times quarterly depreciation indicates the spending is overwhelmingly expansionary rather than replacement-oriented, though the maintenance-versus-growth split is not separately disclosed in the supplied data. That distinction matters because the spending landed during a period when gross margin compressed to 19.5%, which raises an open question about the return hurdle on these assets. The step-change from a 3%-of-revenue capital program to a mid-teens one permanently alters LWAY's cash profile if the spending proves recurring.

Capital returns have otherwise been nonexistent, with zero dividends paid across all ten quarters and only a $115K net acquisition in 2025Q4, so the sudden buyback represents a discretionary deployment choice against a backdrop of negative free cash flow. The timing suggests management view the shares as undervalued, but the supplied data does not disclose how the repurchase was funded, making it premature to infer balance-sheet strain or comfort from this single line. Investors should monitor whether the buyback program persists alongside the elevated capex program, as sustaining both would presumably require external financing.